Skip to main content

Table 6 Results of survival analysis showing association of variations with overall survival

From: Genome sequencing analysis of blood cells identifies germline haplotypes strongly associated with drug resistance in osteosarcoma patients

Name Of Variant # of Samples without mutation # of samples with mutation # of events in samples without mutation # of events in samples with mutation P value from Log Rank (SC) Test Adjusted p-value Hazard Ratio* Gene Name ENCODE annotation dbSNP id Impact Location
chr6_160551093_T_G 44 15 8 7 0.007 0.59 3.723 SLC22A1 Heterochromatin; low signal rs4646272 Modifier Intron variant
chr11_62761161_C_T 42 17 7 8 0.019 0.59 3.161 SLC22A8 Repressed rs2187384 Modifier Intron variant, UTR3
chr4_69528597_A_G 51 8 11 4 0.024 0.59 3.462 UGT2B15 . rs34073924 Modifier Intron variant
chr7_2472429_C_A 53 6 11 4 0.040 0.59 3.124 CHST12 Transcription Elongation rs3735099 Moderate, modifier Missense variant; upstream gene variant
chr7_2472455_A_T 53 6 11 4 0.040 0.59 3.124 CHST12 Transcription Elongation rs3735100 Moderate, modifier Missense variant; upstream gene variant
  1. Variant name is defined as “ChromsomeNumber_Position_ReferenceAllele_AlternateAllele”
  2. The Hazard ratio was obtained from the Cox Proportional Hazards Test – indicates hazard value of having an event (death) in the mutation group compared to the non-mutation group